title: Accelerated drug approval: FDA may get tougher; companies cite hurdles.
authors.forename: Merrill
authors.initials: M
authors.lastname: Goozner
mesh_terms: D026683:Advisory Committees; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068258:Bevacizumab; D000068579:Celecoxib; D000068818:Cetuximab; D018849:Controlled Clinical Trials as Topic; D017277:Drug Approval / Q000379:methods*; D004345:Drug Industry; D015507:Drugs, Investigational / Q000627:therapeutic use*; D005060:Europe; D019317:Evidence-Based Medicine; D006801:Humans; D000077544:Panitumumab; D011720:Pyrazoles / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D011720:Pyrazoles; D013449:Sulfonamides; D000068258:Bevacizumab; D000077544:Panitumumab; D000068579:Celecoxib; D000068818:Cetuximab